What does this research mean for the field?

Icariside II demonstrates neuroprotective potential against Alzheimer's disease, Parkinson's disease, and cerebral ischemia in pre-clinical models by modulating neuroinflammation, oxidative stress, apoptosis, and mitochondrial dysfunction. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review preclinical evidence and characterize the molecular mechanisms underlying the neuroprotective actions of icariside II in Alzheimer's disease, Parkinson's disease, and cerebral ischemia.

August 27, 2026Journal of Biochemical and Molecular ToxicologyOpen Access

Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease

View Full Paper

Ask AI

Bookmark

Authors

ASAshutosh SolankiJSS Academy of Higher Education and Research KSKhushi Sharma JJJagrati JainUniversity of Mississippi

Discussion

Member takes

Implication

Review reveals neuroprotective mechanisms of icariside II across models of Alzheimer's, Parkinson's, and cerebral ischemia, highlighting its therapeutic potential.

Key Points

To review preclinical evidence and characterize the molecular mechanisms underlying the neuroprotective actions of icariside II in Alzheimer's disease, Parkinson's disease, and cerebral ischemia.
Synthesized findings from in vitro and in vivo preclinical studies evaluating the pharmacological targets of icariside II.
Analyzed modulation of key signaling cascades, including PI3K/Akt, Keap1/Nrf2, TLR4/MyD88/NF-κB, Wnt/β-catenin, and BDNF/TrkB/CREB pathways.
Icariside II attenuates oxidative stress by elevating antioxidant enzymes (SOD, GSH, catalase, HO-1) and reducing MDA and lipid peroxidation.
Neuroinflammation and apoptosis are suppressed through down-regulation of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, COX-2, iNOS), reduction of caspase-3 activation, and rebalancing of the Bax/Bcl-2 ratio.
Mitochondrial integrity and blood-brain barrier stability improve via restored Complex I activity, elevated mitofusin-1/2 expression, and up-regulated tight-junction proteins (occludin, claudin-5, ZO-1).

Cite This Study

Solanki et al. (2026) studied this question.

synapsesocial.com/papers/6a8fea0d10c91c1e926220cf https://doi.org/10.1002/jbt.71093

View Full Paper

Ask AI

Bookmark

Implication

Review reveals neuroprotective mechanisms of icariside II across models of Alzheimer's, Parkinson's, and cerebral ischemia, highlighting its therapeutic potential.

Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider